AN2 Therapeutics, Inc. 8K

AN2 Therapeutics reported Q2 2026 results, outlined progress and timelines for multiple Phase 2 clinical programs in polycythemia vera, M. abscessus lung disease and chronic Chagas disease, and noted it has sufficient cash to fund operations into 2029.

On August 11, 2026, AN2 Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026 and provided business updates, highlighting expanded global start-up activities for a planned Phase 2 proof-of-concept trial of oral epetraborole in polycythemia vera (including an IND filing in Q3 2026 and enrollment start in Q4 2026), ongoing enrollment in an 84-patient Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease, positive non-human primate efficacy and Phase 1 safety/pharmacokinetic data for AN2-502998 supporting initiation of a Phase 2 study in chronic Chagas disease in late 2026, and advancement of their boron-chemistry pipeline including an ENPP1 solid tumor candidate, alongside disclosure of increased R&D expenses, a quarterly net loss of $8.2 million, and a cash position of $79.9 million projected to fund operations into 2029.

Filing Facts

CIK

1880438

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-344549

Alert Tier

6